Jorie weight loss clinic hours
Allin, C. Identification and molecular analysis of two apoB gene mutations causing low plasma cholesterol levels. Li, Y. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Journal of Cardiovascular Pharmacology and Therapeutics 20:2, 157-168. Carey. (2015) Mass spectrometry meets the challenge of understanding the complexity of the lipoproteome: recent findings regarding proteins involved in dyslipidemia and cardiovascular disease. Luan, J. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. Kathiresan, J. G. Wang, N. (2016) Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. Grioni, L. CrossRef 321 Kevin Jon Williams, Edward A. (2015) Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Breuer, C. CrossRef 180 Sheng-Hua Yang, Sha Li, Yan Zhang, Rui-Xia Xu, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Chuan-Jue Cui, Jing Sun, Jian-Jun Li. A. 2015. H. CrossRef 360 Ramprasad Gadi, Vincent M. B. (2015) TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. J. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 1:3, 218-229. Michos. Plasma lipids and lipoproteins were assayed in the ARIC central lipid laboratory with commercial reagents, as previously described. CrossRef 109 Michel Farnier. CrossRef 156 Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. (2015) The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Rader. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Jansson, M. Seidah. K. Parhofer, P. Adobe Flash Player is required to view this feature. These data are consistent with the notion that reductions in the incidence of CHD associated with sequence variations in PCSK9 are related to LDL-lowering effects. We are indebted to the staff and participants of the ARIC study for their important contributions and to Michael Brown, Joseph Goldstein, Scott Grundy, James DeLemos, and Darren McGuire for helpful discussions. (2015) The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Adobe Flash Player is required to view this feature. Jukema, R. CrossRef 308 Frederick J Raal, Dirk J Blom. Dron, Robert A. OMICS: A Journal of Integrative Biology 20:9, 498-509. F. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2015) Knocking down disease: a progress report on siRNA therapeutics. Mokry, O. CrossRef 60 Christoph Nowak, Samira Salihovic, Andrea Ganna, Stefan Brandmaier, Taru Tukiainen, Corey D. (2016) Update on the molecular biology of dyslipidemias. Hand, Daniel J. CrossRef 330 James M. CDT Claudia Sun won the individual tournament taking first place, being the only undefeated athlete in the competition across both genders, with a record of 6-0. Stehouwer, Martijn C. 9 percent). Giugliano, JoAnne M. Hong. CrossRef 299 Hyun-Jin Yang, Rinki Ratnapriya, Tiziana Cogliati, Jung-Woong Kim, Anand Swaroop. Hansen. Abstract Background A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. Budha, Maya Leabman, Jin Y. (2015) Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening. 9 percent), the Y142X variant (2. Hegele. (2016) Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Endocrinology and Metabolism Clinics of North America 43, 981-992. (2015) From Human-Induced Pluripotent Stem Cells to Liver Disease Modeling: A Focus on Dyslipidemia. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2016) Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. Wieland, L. Brouwers. (2015) Hyperlipidemia and cardiovascular disease. Wenger, Laurence Sperling. Stegle, P. CrossRef 201 Vittavat Termglinchan, Ioannis Karakikes, Timon Seeger, Joseph C. Cherny, Yan Zhang, Oddgeir Holmen, Ka-Wing Au, Haiyi Yu, Lin Xu, Jia Jia, Robert M. Sabatine. Meigs, M. Simpson. CrossRef 169 Harold E. Hirschhorn, M. CrossRef 12 Hayato Tada, Masa-aki Kawashiri, Masakazu Yamagishi. McCarthy. Oggioni, H. Journal of Epidemiology and Global Health 5:4, 315-325. (2016) Genome Editing: A New Approach to Human Therapeutics. Panel B shows the percentage of participants from these two groups who had no evidence of coronary heart disease at baseline and in whom coronary heart disease developed during the 15-year follow-up period. (2015) Evolocumab (AMG 145) for primary hypercholesterolemia. Golledge, G. , Catapano, Alberico L. Risk Stratification in Clinical Practice. Journal of the American Medical Informatics Association 23:4, 668-670. (2015) Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. A. Journal of the Royal Society of Medicine, 014107681668195. Giger, A. Grarup, A. Michael White. (2015) Hemodynamic Shear Stress. (2016) Macrophage apoptosis and necrotic core development in atherosclerosis: A rapidly advancing field with clinical relevance to imaging and therapy. Hugh R. CrossRef 228 Patrick Wainwright, Aidan Ryan, Rasaq Olufadi, Christopher D Byrne. Adobe Flash Player is required to view this feature. Stitziel, Sekar Kathiresan. B. Ito, Raul D. CrossRef 313 Michael M Page, Gerald F Watts. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Lipids in Coronary Heart Disease. Giugliano. Tukiainen, E. (2015) Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. 02586. CrossRef 241 Erin Crossey, Marcelo J. (2016) A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. CrossRef 46 Justin Parizo, Ashish Sarraju, Joshua W. Parhofer. (2015) Protective alleles and modifier variants in human health and disease. V. Moriarty. Voight. (2015) Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. CrossRef 357 Nuala J. (2015) Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. Whayne. Y. To convert values for LDL cholesterol to millimoles per liter, multiply by 0. Bertier, E. The identification of LDL-lowering alleles of PCSK9 that were sufficiently common allowed us to stratify subjects according to genotype and to assess the association between these alleles and coronary events. Niiranen, Ramachandran S. In this analysis, the dependent variable was the time to an event. Florez. To convert values for LDL cholesterol to millimoles per liter, multiply by 0. Stoellner, D. Almlof, P. ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta. 1 The question regarding the reverse situation naturally arises. Lewis was followed by Danielle Cuomo who shot 1166. Journal of Clinical Lipidology 9:6, S1-S122. (2016) Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. CrossRef 319 Sekar Kathiresan. Carracedo, S. (2015) PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. F. Lizano, H. G. Varughese, Tatsuya Sawamura, Jawahar L. Patel. (2015) PCSK9 inhibition in patients with hypercholesterolemia. (2016) Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Wright, A. (2016) Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery. ,. Cigarette smoking was assessed by standardized questionnaires, and current smokers were classified as positive for smoking. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. The Genetics of Atherosclerosis. Statins are the cornerstone of cholesterol-lowering therapy for the prevention of CHD. CrossRef 375 The Myocardial Infarction Genetics Consortium Investigators. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. e1. 2016. M. J. CrossRef 257 Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Jiwani Shahanawaz, Robert J. CrossRef 73 Bertrand Cariou, Zufeng Ding, Jawahar L. CrossRef 167 Ozlem Bilen, Yashashwi Pokharel, Christie M. 7 percent), and the C679X variant (2. Endocrinology and Metabolism Clinics of North America 45:1, 129-140. The relatively high prevalence of LDL-lowering sequence variations in PCSK9 provided the opportunity to analyze the effects of specific, lifelong reduction in LDL cholesterol levels on the risk of CHD. Young, N. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Seleski, G. Karlberg, H. (2014) Pediatric Lipid Management. (2014) Rare and low-frequency variants in human common diseases and other complex traits. (2015) Genome-wide haplotypic testing in a Finnish cohort identifies a novel association with low-density lipoprotein cholesterol. CrossRef 377 Mi-Hsueh Tai, Po-Kong Chen, Pei-Yi Chen, Ming-Jiuan Wu, Chi-Tang Ho, Jui-Hung Yen. Beltran, M. Neale. (2015) Rare variant association studies: considerations, challenges and opportunities. (2017) Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2016) Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. (2015) An evaluation of alirocumab for the treatment of hypercholesterolemia. (2017) Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Udell, Michael E. 2017. Strom, H. (2016) Recent advances in the pharmacological management of hypercholesterolaemia. eLS, 1-12. Thompson. Kontto, Z. Greenberg, Steve Eyre, John Bowes, Jing Cui, Annette Lee, Dimitrios A. (2016) Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. Dai, X. Plasma levels of total cholesterol, triglycerides, and LDL cholesterol were significantly lower among subjects with a nonsense mutation in PCSK9, but the levels of high-density lipoprotein (HDL) cholesterol were similar in carriers and noncarriers. Free Full Text 346 W. Ho, Wei Zhou, Stacey S. CrossRef 358 Sha Li, Jian-Jun Li. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Boeing, E. CrossRef 338 Sergio Fazio. van Ommen, A. Journal of Clinical and Translational Endocrinology: Case Reports 2, 23-26. Hegele. Korzeniewski, K. Gordon, D. (2016) Leveraging human genetics to guide drug target discovery. CrossRef 349 Ioanna Gouni-Berthold. CrossRef 18 Amir Abbas Momtazi, Maciej Banach, Matteo Pirro, Evan A. (2016) Hypertriglyceridemia: the importance of identifying patients at risk. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Raal. (2015) A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 Danish individuals. Endocrinology and Metabolism Clinics of North America 45:1, 1-16. (2016) Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. Mikhailidis. (2015) Cross-talk between LOX-1 and PCSK9 in vascular tissues. 02586. CrossRef 339 L. (2016) Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations. In Panel A, the distribution of plasma LDL cholesterol levels at baseline among 9223 white subjects who did not have a PCSK9 46L allele (top) is compared with the distribution of levels among the 301 white subjects who were either heterozygous or homozygous for this allele (bottom). Journal of Clinical Lipidology 9:6, 786-793. Ramasamy. CrossRef 243 Nabil G. CrossRef 244 James P. The distribution of plasma levels of LDL cholesterol among black carriers of a PCSK9 variant was shifted toward lower levels ( Figure 1A Figure 1 Distribution of Plasma LDL Cholesterol Levels (Panel A) and Incidence of Coronary Heart Disease (Panel B) among Black Subjects, According to the Presence or Absence of a PCSK9 142X or PCSK9 679X Allele. Bis, S. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Maahs, Lawrence M. R. (2015) Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. Journal of the American College of Cardiology 66:16, 1828-1836. Y. Adobe Flash Player is required to view this feature. CrossRef 193 GPS Shantha, JG Robinson. CrossRef 223 Xin-Lin Zhang, Qing-Qing Zhu, Li Zhu, Jian-Zhou Chen, Qin-Hua Chen, Guan-Nan Li, Jun Xie, Li-Na Kang, Biao Xu. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. 2015. CrossRef 77 Xiangfeng Lu, Jun Li, Huaixing Li, Yang Chen, Laiyuan Wang, Meian He, Yiqin Wang, Liang Sun, Yao Hu, Jianfeng Huang, Feijie Wang, Xuezhen Liu, Shufeng Chen, Kuai Yu, Xueli Yang, Zengnan Mo, Xu Lin, Tangchun Wu, Dongfeng Gu. CrossRef 94 A. The distribution of plasma LDL cholesterol levels among persons heterozygous or homozygous for the R46L-encoding allele was shifted toward lower levels ( Figure 2A Figure 2 Distribution of Plasma LDL Cholesterol Levels (Panel A) and Incidence of Coronary Events (Panel B) among White Subjects, According to the Presence or Absence of a PCSK9 46L Allele. CrossRef 36 Farah Meah, Arshi Basit, Alaleh Mazhari, Mary Ann Emanuele, Nicholas Emanuele. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. (2015) Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. (2015) Finding a Needle in the Haystack. (2015) Genetics of Familial Hypercholesterolemia. CrossRef 67 Sundararajan Srikanth, Prakash Deedwania. 11 Thus, high levels of PCSK9 lead to high plasma levels of LDL cholesterol, whereas low levels of PCSK9 lead to low LDL cholesterol levels. Mentz, Adelino Leite-Moreira, Faiez Zannad, Wolfgang Koenig. A total of 15,792 participants underwent an extensive initial examination, which included collection of medical, social, and demographic data. CrossRef 145 Aimo Kannt, Thomas Wieland. Wierzbicki, P. Wu. (2015) Mendelian randomisation applied to drug development in cardiovascular disease: a review. (2016) Statin therapy across the lifespan: evidence in major age groups. CrossRef 235 A. I. Here we report the effects of these sequence variations on the incidence of CHD in the Atherosclerosis Risk in Communities (ARIC) study, a longitudinal, biracial cohort study designed to assess subclinical and clinical atherosclerosis. CrossRef 122 U. Borglykke, K. Robinson. Greene, Benjamin F. M. Batty, R. S. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015) Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Celis-Morales, M. Walford. The reductions in CHD associated with these PCSK9 sequence variations were larger than those predicted from LDL-lowering trials, 2 presumably reflecting the beneficial effects of lifelong reductions in plasma LDL cholesterol. Knowles. Psaty. Ehm, N. Among black subjects who did not have a nonsense mutation, 9. B. B. Ray. Chen, T. Plenge, John A Chiorini. Progress in Retinal and Eye Research 46, 1-30. Magazine, R. Studies of genetic disorders that specifically lower the plasma level of LDL cholesterol, such as heterozygous familial hypobetalipoproteinemia, would provide an ideal system in which to assess the consequences of low LDL cholesterol levels independently of other factors that may modify disease progression. CrossRef 279 Chi-kin Ip, Dong-mei Jin, Jia-jia Gao, Zhe Meng, Jing Meng, Zhi Tan, Jing-feng Wang, Deng-feng Geng. Nobel, I. Becker. Grarup, T. Martijn Akkerhuis. Aggregate (4655) The Black Knights tallied an aggregate score of 4655, only 11 points behind the leaders Alaska Fairbanks. (2016) Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. David Spence. (2016) Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. South African Journal of Clinical Nutrition 28:1, 34-37. (2015) Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. (2014) Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia. (2015) Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. CrossRef 138 Peter P Toth, Michel Farnier, Joanne E Tomassini, JoAnne M Foody, Andrew M Tershakovec. (2016) PCSK9 inhibitors. J. Chapel Hill: University of North Carolina, ARIC Coordinating Center, School of Public Health, 1987. Battle, S. Wessel, S. CrossRef 300 Qian S Zhang, Brian L Browning, Sharon R Browning. Adobe Flash Player is required to view this feature. Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Pankow, O. CrossRef 277 Richard Kones, Umme Rumana. (2014) PCSK9 Antibodies for the Treatment of Hypercholesterolemia. Kral, Lewis C. e7. W. Zachariah, Philip K. CrossRef 304 Ozlem Bilen, Yashashwi Pokharel, Christie M. Mehta. The State of Whole-Genome Sequencing. M. Discussion The principal finding of this study is that sequence variations in PCSK9 associated with lower plasma levels of LDL cholesterol conferred protection against CHD. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. H. e1. Kasliwal, Manish Bansal, Rajeev Gupta, Siddharth Shah, Sameer Dani, Abraham Oomman, Vikas Pai, Guru Mallapa Prasad, Sunil Singhvi, Jitendra Patel, Sakthivel Sivam, Naresh Trehan. Howitzers, Cadet Store, Sabers, Transcripts, Plumes, Post numbers. 16 Bond MD, Bernes RW, Wilmoth SK, Chambless LE. CrossRef 132 Grant Sutcliffe, Anais Harneit, Heike Tost, Andreas Meyer-Lindenberg. Vasan. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. (2016) Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 272 Sha Li, Yan Zhang, Rui-Xia Xu, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Ping Qing, Geng Liu, Qian Dong, Jian-Jun Li. Determinants of atherosclerosis in the young: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. (2015) In silico. Annual Review of Pharmacology and Toxicology 56:1, 163-190. Zaman, Edwin Wang, Harry Davis, Lorraine E. Adobe Flash Player is required to view this feature. (2016) Positive correlation of plasma PCSK9 levels with HbA. Boehnke, H. CrossRef 316 Ishwarlal Jialal, Shailendra B. CrossRef 323 Phil Mendys, Golsa Joodi, Ross J. (2015) PCSK9 antibodies: A new class of lipid-lowering drugs. CrossRef 41 Leticia Gonzalez, Bernardo Louis Trigatti. Polk, E. Mason-Suares, Shannon Bruse, Scott Mellis, Robert Phillips, Neil Stahl, Andrew Murphy, Aris Economides, Kimberly A. (2016) A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. (2015) Knowledge of PCSK9 and Continued Educational Gaps. Adobe Flash Player is required to view this feature. Tang, He Zhang, Chloe Y. Kuller. 11 These findings, together with the results of the current study, make PCSK9 an attractive new target for LDL-lowering therapy. Scott, D. (2016) Neuroimaging Intermediate Phenotypes of Executive Control Dysfunction in Schizophrenia. CrossRef 17 Andrew Dervan, Jay Shendure. PCSK9 as a Biomarker of Cardiovascular Disease. Dharmarajan, Basil Varkey. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded. Hus-Frechette, John J. (2015) Mendelian Randomization: Present and Future of Epidemiological Studies in Cardiology. Observations in genetically modified mice suggest that inhibition of PCSK9 activity would enhance the LDL-lowering effects of statins. Wells, J. (2016) Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. Fisher. CrossRef 309 Loukas Moutsianas, Vineeta Agarwala, Christian Fuchsberger, Jason Flannick, Manuel A. 6 Overexpression of PCSK9 or the mouse orthologue in the livers of mice results in a marked reduction in LDL receptors in this organ, 7-10 which is the main pathway for the removal of LDL from the plasma, and a corresponding increase in circulating LDL cholesterol levels. (2015) Understanding PCSK9 and anti-PCSK9 therapies. Amstislavskiy, O. Roden. , Brook, Robert D. CrossRef 84 Peter P. 14 The lipid and lipoprotein levels and risk-factor profiles used in this study were obtained at baseline. Annual Review of Genomics and Human Genetics 16:1, 327-350. Familial Low-Cholesterol Syndromes or Hypobetalipoproteinemias. (2015) Applying genetics in inflammatory disease drug discovery. Annual Review of Pharmacology and Toxicology 57:1, 223-244. Linton, Sergio Fazio. Beisel, S. (2016) Novel therapies for severe dyslipidemia originating from human genetics. (2016) Genetics of Lipid and Lipoprotein Disorders and Traits. (2015) Effect of predicted protein-truncating genetic variants on the human transcriptome. CrossRef 205 A. (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. CrossRef 291 Osman Najam, Kausik K. (2016) Using human genetics to discover new therapeutic targets for plasma lipids. CrossRef 379 G. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Lewis placed second and Cuomo placed third both tallying 579 points. Toth. Genetics of Coronary Disease. E. American Heart Journal 168, 878-883. (2016) Mendelian randomization to assess causal effects of blood lipids on coronary heart disease. Willer, Hung-Fat Tse, Wei Gao. CrossRef 153 Sarah Bou Malham, Anne Carol Goldberg. CrossRef 126 R. Greenwood, George Thanassoulis, J. Siminovitch, Milan Gupta, Jacques Genest. Lettre. Bhangale, Ward Ortmann, Andrew Cagan, Vivian Gainer, Elizabeth W. Watts. Justesen, E. (2015) Anacetrapib in familial hypercholesterolaemia: pros and cons. Gibson. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. CrossRef 143 Kaixin Zhou, Helle Krogh Pedersen, Adem Y. (2016) Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. van Poelgeest, Michael R. CrossRef 22 Peter Yin, Verneri Anttila, Katherine M. Brent Richards, Paolo Antonio Muraro. 13 The follow-up data in this study include events up to January 1, 2003. Rivas, Benjamin M. Healy, Peter P. Former Undersecretary of the Army and Pennsylvania Congressman the Honorable Patrick J. CrossRef 5 Maciej Banach, Manfredi Rizzo, Dragana Nikolic, George Howard, VirginiaJ. CrossRef 171 Morris Schweitzer, Sandra Makhoul, Miltiadis Paliouras, Lenore K. CrossRef 163 Sean Allen, Yu-Gang Liu, Evan Scott. Miklos, S. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 161 C. CrossRef 337 Siddharth Singh, Vera Bittner. Siervo. (2016) PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. CrossRef 266 Mark I. CrossRef 114 Zufeng Ding, Shijie Liu, Xianwei Wang, Pankaj Mathur, Yao Dai, Sue Theus, Xiaoyan Deng, Yubo Fan, Jawahar L. (2015) Next Steps in Primary Prevention of Coronary Heart Disease. Tarugi, M. (2015) PCSK9: A key factor modulating atherosclerosis. D. Ahmad, Vincenzo Forgetta, George Davey Smith, Aaron Leong, Celia M. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 378 Jennifer G. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Gut, X. Click HERE to have West Point Cadet News emailed to you You will be directed to a secure Feedburner Form - seperate from all WPAOG email systems. Cobble. Dawed, Ewan R. (2015) Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Werner. CrossRef 24 Marie-Jeanne Bertrand, Jean-Claude Tardif. Virgil Brown. Stenson, D. Fischer, U. Biddinger. (2016) Genome editing in cardiovascular diseases. CrossRef 107 Yuan Guo, Qiong Liu, Danyan Xu. CrossRef 259 Sabrina Prudente, Diego Bailetti, Christine Mendonca, Gaia Chiara Mannino, Andrea Fontana, Francesco Andreozzi, Timothy Hastings, Luana Mercuri, Federica Alberico, Giorgio Basile, Massimiliano Copetti, Giorgio Sesti, Alessandro Doria, Vincenzo Trischitta. (2015) Coronary Heart Disease and Genetic Variants with Low Phospholipase A 2 Activity. Among the 13,761 eligible subjects (10,045 whites and 3716 blacks), there were 419 (255 whites and 164 blacks) from whom genomic DNA was not available, and genotypes were missing because of assay failure for the R46L variant (2. Hazard ratios based on the regression coefficients from the Cox modeling procedure are reported. CrossRef 133 Atsuko Konta, Kouichi Ozaki, Yasuhiko Sakata, Atsushi Takahashi, Takashi Morizono, Shinichiro Suna, Yoshihiro Onouchi, Tatsuhiko Tsunoda, Michiaki Kubo, Issei Komuro, Yoshinobu Eishi, Toshihiro Tanaka. (2016) New lipid therapies: PCSK9 inhibitors. Schiller, Bryce Chackerian, Alan T. Adobe Flash Player is required to view this feature. These data suggest that lifelong reduction of LDL levels confers greater benefit than does a similar reduction instituted later in life. CrossRef 78 Alanna Strong, Kiran Musunuru. (2015) Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. Williams, Charles C. (2015) Beneficial metabolic phenotypes caused by loss-of-function. G. (2016) Shedding light on FGF21: A potential negative regulator of PCSK9. M. Freeman, Geoffrey A. Denny, Lisa Bastarache, Dan M. CrossRef 359 Je Rossouw. Russell Wada, Amos Baruch, Kun Peng, Whittemore G. Ferdinand, Samar A. Adobe Flash Player is required to view this feature. Eugene Chen. As was observed for the nonsense mutations, the R46L substitution was associated with a significant reduction in plasma levels of total cholesterol (9 percent) and LDL cholesterol (15 percent). (2015) The past, present and future of lipid-lowering therapy. Stay up to date with all West Point news and stay connected with fellow grads. (2016) Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. Desai, Marc S. (2015) The Effects of Estrogen on Serum Level and Hepatocyte Expression of PCSK9. (2015) Association of Zinc Finger, C3HC-Type Containing 1 (ZC3HC1) rs11556924 Genetic Variant With Hypertension in a Finnish Population, the TAMRISK Study. (2016) Aktuelle Lipidtherapie bei Diabetes mellitus. Norata, A. Adobe Flash Player is required to view this feature. To convert values for LDL cholesterol to millimoles per liter, multiply by 0. (2015) A genetic basis for coronary artery disease. CrossRef 239 Ralph Burkhardt. (2016) Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration. CrossRef 341 Ignacio Iturrieta-Zuazo, Stefan Walter. Baum. Sandholt, J. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Remaley. Kremer, Anne Barton, Marieke J. (2017) PCSK9: Regulation and Target for Drug Development for Dyslipidemia. Lupski, Yaping Yang. CrossRef 295 Min Wang, Shui-Ping Zhao, Ming-Yue Tan, Fang Huang. CrossRef 8 Handrean Soran, Ricardo Dent, Paul Durrington. Ledbetter, Aris Baras, David J. (2016) Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Ongen, H. Watts. Media in This Article Figure 1 Distribution of Plasma LDL Cholesterol Levels (Panel A) and Incidence of Coronary Heart Disease (Panel B) among Black Subjects, According to the Presence or Absence of a PCSK9 142X or PCSK9 679X Allele. Adobe Flash Player is required to view this feature. (2016) Serum calcium and risk of migraine: a Mendelian randomization study. McCarthy, Samuli Ripatti. CDTs Griffin and Kurtzahn finished at 2-0 in the weapon of Foil, while CDT Papa was 2-1 in the weapon of Sabre. Adobe Flash Player is required to view this feature. The protocol for the study was approved by the institutional review boards of all centers, and all participants provided written informed consent that included consent for genetic studies. Blankenberg, M. (2015) Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. The significant reduction in the incidence of CHD among black subjects with the nonsense mutations suggests that a lifelong history of reduced LDL cholesterol levels significantly lowers the risk of CHD, even in the presence of multiple risk factors. McKenney. Hugh R. (2014) Diabetic dyslipidemia. Barrett, Gerald F. CrossRef 280 Carlos Guijarro, Luis Miguel Ruilope. Quasney. Dahmer, Timothy Cornell, Michael W. Cheung, Ming Xu, Jenny C. Hambright, J. Julius. (2016) Discovery of rare variants for complex phenotypes. Gonzalez, S. She reported no family history of heart disease and had a myocardial infarction at the age of 53 years. 2016. Ballantyne. (2017) Intensive LDL-cholesterol lowering therapy and neurocognitive function. Floyd, Bruce M. Despite its more moderate LDL-lowering effect, the PCSK9 46L allele was associated with a significant reduction in the incidence of CHD ( Figure 2B ). Data from cross-sectional and cohort studies are consistent with the hypothesis that low levels of LDL cholesterol are protective, 3 but these data are potentially confounded by other factors related to low LDL cholesterol levels that may independently contribute to reductions in cardiovascular events. (2016) Promising new therapies for the treatment of hypercholesterolemia. Cox proportional-hazards modeling was used to test the null hypothesis that the incidence rate of CHD did not differ between carriers and noncarriers. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Huff. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. Journal of Clinical Lipidology 10:3, 547-555. Watts. Stein, Frederick J. (2016) Zebrafish small molecule screens: Taking the phenotypic plunge. CrossRef 15 M Levisetti, T Joh, H Wan, H Liang, P Forgues, B Gumbiner, PD Garzone. (2016) A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies. Kastelein, Christie M. Goedecke. Lipoproteins. (2016) Genetic and epigenetic factors in the regulation of the immune response. (2015) Combined PCSK9 and APOE Polymorphisms are Genetic Risk Factors Associated with Elevated Plasma Lipid Levels in a Thai Population. Meyer. 8 percent). Surendran, R. (2016) Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Annual Review of Genomics and Human Genetics 17:1, 353-373. CrossRef 381 Yuan-Lin Guo, Wei Zhang, Jian-Jun Li. C. Search for grads by name, class year, company and many other criteria. Principles of Primary and Secondary Prevention of Cardiovascular Disease. Key, J. Mehta. Article Activity 970 articles have cited this article Article Experimental, genetic, and epidemiologic data support the concept that an elevated plasma level of low-density lipoprotein (LDL) cholesterol is a primary causal factor in the pathogenesis of coronary heart disease (CHD). Aronow. Kesselheim. J. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Franklin, Aaron S. 2 Ironically, statin treatment increases the expression of both the LDL-receptor gene ( LDLR ) and PCSK9. (2016) Statin combination therapy and cardiovascular risk reduction. (2015) PCSK9 Inhibitors: The Next Frontier in Low-Density Lipoprotein Lowering. (2015) Low-density lipoprotein cholesterol lowering therapies. (2015) Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes. The assays were performed on a 7900HT Fast Real-Time PCR instrument with probes and reagents purchased from Applied Biosystems. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. Eapen, Nima Ghasemzadeh, Naveen Bellam, Neal Bhatia, Kiran Valiani, Jia Shen, Richard J. Custodis, C. (2016) Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease. Bennett, Hooman Allayee. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. (2016) PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering. Hiller, J. Adobe Flash Player is required to view this feature. (2015) Lipid Management in Diabetes with a Focus on Emerging Therapies.
[img][/img]
7 percent had a coronary event during the 15-year follow-up period ( Figure 1B ). A. Current Status of Genome Editing in Cardiovascular Medicine. CrossRef 219 Eveline P. (2016) The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. (2015) Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes. Adobe Flash Player is required to view this feature. Tikhonov, M. Ito, Harold E. CrossRef 103 Massimiliano Ruscica, Nicola Ferri, Chiara Macchi, Marica Meroni, Claudia Lanti, Chiara Ricci, Marco Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion, Paolo Magni, Luca Valenti, Paola Dongiovanni. Pearson. Ahmad, V. Therefore, analysis of these nonsense mutations was restricted to black subjects. Grammer, Ulf Landmesser, Hans Dieplinger, Eberhard Windler, Ulrich Laufs. Bays, W. CrossRef 324 J. Paul Wadwa, Sudha B. (2016) JCL roundtable: PCSK9 inhibitors in clinical practice. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. No potential conflict of interest relevant to this article was reported. M. (2016) Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Willems, J. CrossRef 208 Livio Garattini, Anna Padula. (2016) PCSK9 inhibitors in the prevention of cardiovascular disease. 3 percent vs. CrossRef 134 Ezim Ajufo, Daniel J Rader. (2016) PCSK9-Inhibitoren. Buermans, I. CrossRef 265 Philipp Stawowy. Andersson, N. Andersson, H. Adobe Flash Player is required to view this feature. (2015) Proprotein convertases in atherogenesis. (2016) Engineering Nanomaterials to Address Cell-Mediated Inflammation in Atherosclerosis. (2014) Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease. Stroes. (2016) Genetics for the Identification of Lipid Targets Beyond PCSK9. Figure 2 Distribution of Plasma LDL Cholesterol Levels (Panel A) and Incidence of Coronary Events (Panel B) among White Subjects, According to the Presence or Absence of a PCSK9 46L Allele. CrossRef 110 Nosratola D. CrossRef 306 Ricardo Ladeiras-Lopes, Stefan Agewall, Ahmed Tawakol, Bart Staels, Evan Stein, Robert J. Minikel, P. Richards. Voight. (2016) Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Farkouh. CrossRef 85 Dan M. (2017) The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities. Rusyn, F. (2016) Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese. CrossRef 372 Ioanna Gouni-Berthold, Heiner Berthold. Apolipoprotein-B. -H. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Antonarakis, R. Foody. Getz, A. Domanski, Valentin Fuster, Francisco Diaz-Mitoma, Scott Grundy, Donald Lloyd-Jones, Muhammad Mamdani, Robin Roberts, Kevin Thorpe, Judith Hall, Jacob A. The American Journal of Human Genetics 98:2, 347-357. Adobe Flash Player is required to view this feature. Several studies have estimated the potential effect of cholesterol-lowering interventions on the burden of CHD in the population. Persons who were heterozygous or homozygous for PCSK9 46L had a 47 percent reduction in the rate of coronary events (6. Adobe Flash Player is required to view this feature. CrossRef 253 Sasha A Singh, Katsutoshi Miyosawa, Masanori Aikawa. (2017) A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy. Sullivan, J. Coenen, Barbara Franke, Lambertus A. S. CrossRef 44 Alon Eisen, Robert P. Grant. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Mehta. David Marais. 2015. (2016) ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Estivill. 02586. Y. Hypertension was defined by a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or use of antihypertensive medication. (2016) PCSK9 Inhibitors. CrossRef 182 Henning Jansen, Wolfgang Lieb, Heribert Schunkert. Pirillo, G. Panel B shows the percentage of participants from these two groups who had no evidence of coronary heart disease at baseline and in whom coronary heart disease developed during the 15-year follow-up period. Laufs, F. Due to his outstanding performance on and off the ice, firstie goaltender Parker Gahagen has been named a 2017 Hobey Baker Nominee, announced by the foundation Monday. CrossRef 111 Lewis J Frey, Elmer V Bernstam, Joshua C Denny. PCSK9 is a glycoprotein that is expressed at its highest levels in the liver, intestine, and kidney. S. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 13 William F. (2016) Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. Walters, J. Allen Solida (568) and Mike Garner (568) round out the scores for Army. Catapano. 7 mmol per liter). This finding is consistent with the observation that coronary atherosclerosis develops early in life 20-23 and suggests that earlier introduction of an intervention that lowers lipid levels even moderately may confer increased protection from CHD. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. European Heart Journal - Cardiovascular Pharmacotherapy 2, 44-53. T. A. CrossRef 334 Enas A. E. CrossRef 172 Q Feng, W Q Wei, C P Chung, R T Levinson, L Bastarache, J C Denny, C M Stein. Sever, Terje R. (2016) Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe. Dermot G. Siewert, Aarno Palotie, George Davey Smith, Benjamin F. Reductions in plasma LDL cholesterol levels have been strongly associated with a reduced incidence of coronary events in clinical trials, 2 but the long-term effects of low LDL cholesterol levels on coronary atherosclerosis have been less clearly defined. J. The exclusion criteria included use of lipid-lowering drugs (454 persons) and the presence of symptomatic cardiovascular disease (1430 persons) at baseline. Payne Nunn was the next Black Knight, coming in 14 shooting 572. (2017) PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. (2016) The Application of Genomics in Diabetes: Barriers to Discovery and Implementation. (2016) Familial Hypercholesterolemia. Neely, Vijay Kunadian. Adobe Flash Player is required to view this feature. 24 The participants described in the current report were 45 to 64 years old at the inception of the study and were followed for an average of 15 years. Bays. The Army West Point Fencing Team hosted their annual Invitational in Arvin and took First Place as the only undefeated team in the tournament. A. CrossRef 288 Nicole Ellman, Dheshnie Keswell, Malcolm Collins, Mehreen Tootla, Julia H. (2016) Epidemiology: Then and Now. In Panel A, the distribution of plasma LDL cholesterol levels at baseline among 9223 white subjects who did not have a PCSK9 46L allele (top) is compared with the distribution of levels among the 301 white subjects who were either heterozygous or homozygous for this allele (bottom). If you are using an operating system that does not support Flash, we are working to bring you alternative formats. (2016) Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. (2016) Managing risks in drug discovery: reproducibility of published findings. CrossRef 64 Giuseppe Danilo Norata, Hagai Tavori, Angela Pirillo, Sergio Fazio, Alberico L. Adobe Flash Player is required to view this feature. Kleber, Sarah Seiler, Insa Emrich, Simone Lennartz, Christian Werner, Adam M. Adobe Flash Player is required to view this feature. CrossRef 199 Hayato Tada, Masa-aki Kawashiri, Tetsuo Konno, Masakazu Yamagishi, Kenshi Hayashi. (2017) Rational medical therapy is the key to effective cardiovascular disease prevention. Kilpinen, S. 2015. (2016) Experimental Biology for the Identification of Causal Pathways in Atherosclerosis. e5. Bays. G. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 148 Daniel Gaudet. The study does not address whether the cardioprotective effects of the LDL-lowering PCSK9 sequence variations persist in older age groups. Endocrinology and Metabolism Clinics of North America 43, 1007-1033. Joshi, Erin D. CrossRef 367 Liya Wu, Klaus G. Topol. Barroso, S. In Panel A, the distribution of plasma LDL cholesterol levels at baseline among 3278 black subjects who did not have a PCSK9 142X or PCSK9 679X allele (top) is compared with the distribution of levels among the 85 black subjects who had one of these two alleles (bottom). Schaper, Coen D. The Army West Point rifle team came in second Sunday morning at a mini tournament hosted by Akron. -G. Toth. Ooi, Marion Cousins, Colette Favreau, Kathy Henry, Anne Landry, Alexander Sorisky. (2016) Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. CrossRef 254 Michael M Page, Gerald F Watts. N. Moreover, it is not known whether the beneficial effect of decreased LDL cholesterol levels on cardiovascular disease results in an overall reduction in mortality rates. 25 The increased expression of PCSK9 may attenuate the LDL-lowering effect of statins. Stancakova, Y. (2015) Vision from next generation sequencing: Multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and disease. Averna. Moriarty, James M. High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study (ARIC). The difference between carriers and noncarriers in the incidence of heart disease may decline with aging, as the absolute rates of disease increase. These disorders are uncommon and genetically heterogeneous, however, and it has not been possible to determine their effects on CHD. Pulyakhina, D. Lopez, John Penn, Semanti Mukherjee, Nehal Gosalia, Manoj Kanagaraj, Alexander H. Chalifour. Van Hout, Jeffrey Staples, Claudia Gonzaga-Jauregui, Raghu Metpally, Sarah A. Brazma, T. (2015) Targeting PCSK9 for Therapeutic Gains. Watts. (2015) Developing Medicines That Mimic the Natural Successes of the Human Genome. Perry, Luke Marney, Albert Koulman, Edward D. Gut, K. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Freitag, L. C. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. CrossRef 264 Anders Wittrup, Judy Lieberman. Lipoprotein Metabolism and the Treatment of Lipid Disorders. Maruthur, K. (2016) Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. P. (2015) PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Esser, T. (2016) Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. McCarthy, J. Yaghootkar, J. Kellis, G. (2015) Association between worldwide dietary and lifestyle patterns with total cholesterol concentrations and DALYs for infectious and cardiovascular diseases: An ecological analysis. Jorgensen, J. These data suggest that relatively moderate reductions in LDL cholesterol level (20 to 40 mg per deciliter) would markedly reduce the incidence of CHD in the population if sustained over a lifetime. Harper, Shalini Nayee, Eric J. (2016) The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants. (2015) PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G. Wareham, D. 12 Methods Subjects The ARIC study is a prospective study of atherosclerosis initiated in 1987. CrossRef 222 Fiorella Devito, Annapaola Zito, Gabriella Ricci, Rosa Carbonara, Ilaria Dentamaro, Francesca Cortese, Santa Carbonara, Marco Matteo Ciccone. Adobe Flash Player is required to view this feature. CrossRef 141 Jin M. Chan, P. CrossRef 45 J. Santos. Records of hospitalizations and deaths were abstracted as previously described. CrossRef 290 Toru Miyoshi, Keigo Nakamura, Masayuki Doi, Hiroshi Ito. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Bernelot Moens, Julian C. T. Panel B shows the percentage of participants from these two groups who had no evidence of coronary heart disease at baseline and in whom coronary heart disease developed during the 15-year follow-up period. Cooper, K. If elevations in LDL cholesterol cause CHD, do reductions in LDL cholesterol prevent this disease. Albers,, Gil McVean, Michael Boehnke, David Altshuler, Mark I. Nissen, Ransi Somaratne, Leslie Cho, John J. McQuillan, Joseph Hung, John P. ,, Gibbs, Richard A. (2016) Integrating electronic health record genotype and phenotype datasets to transform patient care. -H. CrossRef 355 D. (2016) Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. Bryan Brewer, Ron Waksman. (2016) Common and Rare Variant Association Study for Plasma Lipids and Coronary Artery Disease. Garcia, J. CrossRef 29 Josefa Girona, Daiana Ibarretxe, Nuria Plana, Sandra Guaita-Esteruelas, Nuria Amigo, Mercedes Heras, Luis Masana. Advances in Hypercholesterolemia. CrossRef 168 Harold E. Wasserman, Gilles Lambert. (2015) Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. CrossRef 37 Ference, Brian A. CrossRef 75 Paul Cerrato, Mary Mihalovic. , Chapman, M. Adobe Flash Player is required to view this feature. CrossRef 322 Ming-Lin Liu, Daniel J. (2015) Genetic Testing in Hyperlipidemia. 2016. , Voros, Szilard, Giugliano, Robert P. Figueredo. (2016) Novel Therapies for Familial Hypercholesterolemia. More than one half of the black participants in the ARIC study had hypertension, almost one third smoked, and nearly 20 percent had diabetes. (2015) Update of Clinical Trials of Anti-PCSK9 Antibodies. A Stepwise Approach to a Career in Translational Research. (2014) Perspektiven zu cholesterinwirksamer Behandlung 2014. (2016) The Application of the LDL Principle. CrossRef 250 Ann M Moyer, Linnea M Baudhuin. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Roden. Giugliano, Anthony Keech, Narimon Honarpour, Huei Wang, Thomas Liu, Scott M. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Virgil Brown. Enas, T. Adobe Flash Player is required to view this feature. Adobe Flash Player is required to view this feature. Wareham, Claudia Langenberg, Cosetta Minelli. Chu, P. Flicek, T. CrossRef 159 DM Roden, JC Denny. Jin, D. CrossRef 155 Andrea Denegri, Iveta Petrova-Slater, Elena Pasotti, Maria Grazia Rossi, Giovanni Battista Pedrazzini, Tiziano Moccetti, Marco Moccetti. Amar, Maureen Sampson, Julianne Peabody, John T. Lebherz. CrossRef 370 Charlotte Andersson, Asya Lyass, Ramachandran S. Ballantyne, Joel Neutel, Anne Cropp, William Duggan, Ellen Q. Cholesterol Metabolism and Vascular Disease. The age, sex distribution, body-mass index, and prevalences of hypertension, diabetes, and smoking were not significantly different between white subjects with the PCSK9 46L allele and those without it ( Table 2 ). CrossRef 211 Michel Farnier. (2014) New Therapies for Reducing Low-Density Lipoprotein Cholesterol. CrossRef 225 Osman Najam, Gilles Lambert, Kausik K Ray. (2015) Effects of lipoprotein apheresis on PCSK9 levels. (2016) A functional SNP in FLT1 increases risk of coronary artery disease in a Japanese population. Kee, N. To convert values for LDL cholesterol to millimoles per liter, multiply by 0. Gibbs, Sameer Doshi, Mita Kuchimanchi, Anita Grover, Maurice G. Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor. Conversely, mice lacking Pcsk9 have increased levels of hepatic LDL receptors, and they remove LDL from the plasma at an accelerated rate. Tomas, Ming-Hui Zhao. Adobe Flash Player is required to view this feature. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. CrossRef 303 Victoria Enchia Bouhairie, Anne Carol Goldberg. W. Bridge, M. Rosenson, Wolfgang Koenig. CrossRef 328 Fatima Rodriguez, Joshua W. Rader, B. Albers, B. Philip Eaton. B. Cohen. 2015. -C. 2016. Adobe Flash Player is required to view this feature. CrossRef 320 Paul Johnson, Jack Kuritzky, Marschall Runge. (2016) Genetic Testing in Hyperlipidemia. Steiner, Salim Virani. Raal. Kahlem, V. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. M. Martinson. Mehta. CrossRef 347 Wen Guo, Jinxiang Fu, Xiaoli Chen, Beibei Gao, Zhenzhen Fu, Hongqi Fan, Qin Cui, Xiaohui Zhu, Yang Zhao, Tao Yang, Daping Fan, Hongwen Zhou. (2016) Proprotein convertase subtilisin kexin type 9 inhibitors. Wang, Robert A. Johnson. Underberg, Michael Koren, Seth J. (2015) Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. (2016) Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. Wasserman, Robert Scott, Marilyn Borgman, Stephen J. Langenberg, M. Crowley. Army had two athletes on the podium for Smallbore. (2016) Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. CrossRef 336 Salam Idriss, Kazem Zibara, Bertrand Cariou, Karim Si-Tayeb. CrossRef 255 Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis. (2015) Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. CrossRef 186 I. (2016) Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Free Full Text 376 Hiroshi Mabuchi, Atsushi Nohara. Barann, T. (2016) The 10. Zhou, A. (2015) Insights into blood lipids from rare variant discovery. Kaaks, F. Jones, Penny Kris-Etherton, Geeta Sikand, Ralph La Forge, Stephen R. CrossRef 189 Matthew Porteus. CrossRef 374 Jose Castro-Perez, Nathan Hatcher, Nana Kofi Karikari, Sheng-Ping Wang, Vivienne Mendoza, Henry Shion, Alan Millar, John Shockcor, Mark Towers, David McLaren, Vinit Shah, Stephen Previs, Karen Akinsanya, Michele Cleary, Thomas P. L. (2016) Update on PCSK9 therapies for the treatment of dyslipidemia. Murphy was visiting West Point for the 2017 National Conference on Ethics in America. Kurbatova, T. Waterworth. H. Kerrison, T. Endocrinology: Adult and Pediatric, 715-736. P. Zhang. Cena, J. CrossRef 283 Amand F Schmidt, Lucy S Pearce, John T Wilkins, John P Overington, Aroon Hingorani, Juan Pablo Casas, Juan Pablo Casas. Garcia-Garcia, Eric Boersma, Robert-Jan van Geuns, Patrick W. CrossRef 136 Pradeep Natarajan, Sekar Kathiresan. The possibility exists that the nonsense mutations and R46L-encoding allele of PCSK9 reduce CHD by a mechanism unrelated to the LDL-lowering effect. (2016) Pathway and network-based strategies to translate genetic discoveries into effective therapies. American Journal of Respiratory and Critical Care Medicine 192, 1275-1286. Nonetheless, PCSK9 may also have direct atherogenic effects that are independent of plasma levels of LDL cholesterol. Adobe Flash Player is required to view this feature. The ballot of the top-10 finalist will be released at a later date after the initial fan vote. CrossRef 144 Stephen Burgess, Eric Harshfield. (2017) Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Adobe Flash Player is required to view this feature. Syvanen, G. CrossRef 348 S. (2015) PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics. Guo, Andrew Dauber. Adobe Flash Player is required to view this feature. Y. (2016) Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Statistical Analysis Routine comparisons of risk-factor levels between carriers of a PCSK9 variant and noncarriers were performed with contingency chi-square tests for discrete variables and t-tests for continuous variables. Barricarte, I. (2016) Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. CrossRef 221 Erica Hoe, Robert A. (2016) The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. Adobe Flash Player is required to view this feature. (2015) ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. (2016) The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Diabetes mellitus was defined by a fasting glucose level of 126 mg per deciliter (7 mmol per liter) or higher, a nonfasting glucose level of 200 mg per deciliter (11 mmol per liter) or higher, use of hypoglycemic agents, or a history of physician-diagnosed diabetes mellitus. (2015) Genetic considerations in the treatment of familial hypercholesterolemia. Catapano. (2016) Strengthening national capacities for researching on Social Determinants of Health (SDH) towards informing and addressing health inequities in Tanzania. CrossRef 62 James Latimer, Jonathan A. Nikkari. CrossRef 345 Polfus, Linda M. Hasler, A. CrossRef 318 Na-Qiong Wu, Sha Li, Jian-Jun Li. (2015) Familial Hypercholesterolemia. (2016) Genetics—Current and Future Role in the Prevention and Management of Coronary Artery Disease. CrossRef 344 Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Changqing Sun, Yannian Wang, Jawahar L. Therefore, the analysis included all eligible persons who entered the follow-up period, except for 45 persons who specifically asked that their DNA not be used for research. (2016) Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. CrossRef 369 Gerald Klose, Rainer Schulz, Wolfgang Koenig. CrossRef 246 Lasse Folkersen, Shameek Biswas, Klaus Stensgaard Frederiksen, Pernille Keller, Brian Fox, Jan Fleckner. CrossRef 202 Teik Chye Ooi, Hussein Abujrad. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. 2015. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Hegele, Murray W. Journal of the American College of Cardiology 66:24, 2710-2712. CrossRef 298 Gisle Langslet, Maurice Emery, Scott M Wasserman. Masanja, Masuma Mamdani. Journal of the American College of Cardiology 65, 1562-1566. CrossRef 32 Michel Farnier. Dixon, Cory Trankle, Leo Buckley, Eric Parod, Salvatore Carbone, Benjamin W. 9 mmol per liter) and an HDL cholesterol level of 27 mg per deciliter (0. Schatz, U. (2015) Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients. Waldmann, K. (2016) Association of rs1122608 with Coronary Artery Disease and Lipid Profile: A Meta-analysis. Adobe Flash Player is required to view this feature. (2016) Evolocumab for the treatment of homozygous familial hypercholesterolaemia. CrossRef 50 Terry McCormack, Ricardo Dent, Mark Blagden. Van Tassell, Antonio Abbate. Nicholls. Nonsense mutations in PCSK9 were not associated with cardiovascular risk factors (other than LDL cholesterol level) in a prior study. CrossRef 56 Wan Peng, Fu Qiang, Wei Peng, Zhang Qian, Zhu Ke, Lu Yi, Zhong Jian, Qiu Chongrong. (2016) Found in Translation: A Type 1 Diabetes Genetic Risk Score Applied to Clinical Diagnosis. Walsh. CrossRef 340 Samir Wadhawan, Heiko Runz, Julja Burchard. CrossRef 353 Paul L Auer, Guillaume Lettre. A total of eight white subjects were homozygous for the PCSK9 46L allele. (2016) Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism. (2014) Starting Primary Prevention Earlier With Statins. V. Stewart, John R. Adobe Flash Player is required to view this feature. Coronary artery disease in combat casualties in Vietnam. (2016) Statins and Their Effect on PCSK9—Impact and Clinical Relevance. CrossRef 267 Arinze Nkemdirim Okere, Courtney Serra. McKenney. 11. (2016) Increased genetic risk for obesity in premature coronary artery disease. Kees Hovingh. (2016) Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study—Observational Study. Sultan, G. Further investigation in the ARIC study populations and in cohorts of elderly persons will be required to answer these questions. The analysis properly accounted for participants who were lost to follow-up or who had not had an event by the end of the study period. Nasser. Recent clinical trials have shown that the reduction in the rate of coronary events is directly related to the magnitude of the reduction in LDL cholesterol levels. (2015) The Genome as Pharmacopeia: Association of Genetic Dose with Phenotypic Response. CrossRef 20 Marcello Arca. Ribeca, I. Valerio, Arash Velayati, Diwakar Jain, Wilbert S. E. Shapiro, Sergio Fazio, Hagai Tavori. Adobe Flash Player is required to view this feature. Knowles. D. (2015) The Power of Gene-Based Rare Variant Methods to Detect Disease-Associated Variation and Test Hypotheses About Complex Disease. Population-based studies consistently demonstrate a positive correlation between plasma levels of LDL cholesterol and the prevalence of CHD, and all five single-gene disorders that result in elevated LDL levels are associated with premature coronary atherosclerosis. (2017) Evidence-based goals in LDL-C reduction. CrossRef 115 (2016) A federated ecosystem for sharing genomic, clinical data. Forgetta, G. 2017. Taylor, Paul D. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Pedersen, T. CrossRef 289 Nutjaree Jeenduang, Sureerut Porntadavity, Smith Wanmasae. In Panel A, the distribution of plasma LDL cholesterol levels at baseline among 3278 black subjects who did not have a PCSK9 142X or PCSK9 679X allele (top) is compared with the distribution of levels among the 85 black subjects who had one of these two alleles (bottom). (2016) Liver fat accumulation is associated with circulating PCSK9. M. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. e1. Ballantyne. (2015) The hinterland of familial hypercholesterolaemia. van Capelleveen, Erik S. Shablin, G. (2015) PCSK9 inhibitors for LDL lowering. Panel B shows the percentage of participants from these two groups who had no evidence of coronary heart disease at baseline and in whom coronary heart disease developed during the 15-year follow-up period. Thanassoulis, J. (2016) A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Greger, M. CrossRef 82 Enrico Agabiti Rosei, Massimo Salvetti. H. K. CrossRef 269 Ellen M Schmidt, Cristen J Willer. (2016) LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. Journal of the American College of Cardiology 65:24, 2638-2651. CrossRef 371 Hagai Tavori, Shirya Rashid, Sergio Fazio. Li, A. CrossRef 234 Terry A. C. D. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Orho-Melander. CrossRef 361 Eli M Roth, James M McKenney. (2015) Practical recommendations for the management of hyperlipidemia. CrossRef 69 Xiaopeng Zhu, Hua Bian, Xin Gao. Rader. Geschwindner, G. 2016. CrossRef 314 Ariel Brautbar, Emili Leary, Kristen Rasmussen, Don P. CrossRef 270 Tarja Kunnas, Seppo T. H. Zhao, S. Bradbury, K. (2015) A cholesterol-lowering VLP vaccine that targets PCSK9. 2016. Lehrach, S. Stein, Frederick J. D. Among white subjects, the prevalences of all the major cardiovascular risk factors, including hypertension, were similar in carriers and noncarriers. CrossRef 150 Thomas F. Beilby, P. G. Barrett, Gerald F. P. CrossRef 164 Lewis H. 2015. (2015) Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. CrossRef 160 Jose C. Kushner, Michael E. (2016) Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Evans, George Davey Smith. CrossRef 190 Amita Singh, Michael Davidson. (2016) Cardiovascular risk reduction: the future of cholesterol lowering drugs. The number of deaths observed during the follow-up period was slightly lower among carriers than among noncarriers both in black subjects and in white subjects, but the difference did not reach statistical significance. , Davey Smith, George, Fazio, Sergio, Sabatine, Marc S. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population. CrossRef 146 Christopher B Cole, Majid Nikpay, Alexandre FR Stewart, Ruth McPherson. Murphy, Javier Martin, Alexandra Zhernakova, Lars Klareskog, Leon
